Insofar as this was the largest premium ever paid in a medium- or large-sized biotech buyout, I would relish being a lawyer for the defendants if the suit ever went to trial!
Two Inhibitex Inc. shareholders sued claiming Bristol-Myers Squibb Co.’s $2.5 billion buyout offer undervalues the drugmaker. Shareholders Charles C. Osborne Jr. and Hortensia Osborne are asking a judge to bar the proposed transaction. The deal will prevent Inhibitex shareholders from benefiting from the company’s long-term prospects, according to the complaint filed yesterday in Delaware Chancery Court.